Lifeward posts Q4 revenue $5.1M (-33% YoY); enters Oramed deal for oral insulin platform

Lifeward Ltd.

Q4 revenue $5.1M (-33% YoY); full year $22.0M (-14% YoY). ReWalk exoskeleton sales +20% in Q4.
Net loss narrowed 65% to $5.3M ($3.60/share) in Q4; full year $19.9M ($17.16/share).
GAAP gross margin 38.2% in 2025 (non-GAAP 40.9%); operating expenses down 25%.
Cash $2.2M at Dec 31, 2025; expects up to $47M funding from Oramed upon closing strategic deal.
Shareholders approved Oramed deal: Lifeward acquires POD oral insulin tech; Oramed gets up to 49.99% equity.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.